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applied from Finnish medicine tariff. RESULTS: All the patients
with baseline LDL-C level of 4,0 mmol/l (SD = 0,25 mmol/l)
reached PTT when using rosuvastatin 10 mg, 20 mg or 40 mg.
Corresponding numbers for simvastatin 20 mg, 40 mg and
80 mg were 4%, 57%, and 99%, respectively. The incremental
annual cost of rosuvastatin 10 mg compared to generic simv-
astatin 40 mg was 710€ per additional PTT. When patient’s
baseline LDL-C level exceeded 4.2 mmol/l rosuvastatin pro-
duced the lowest annual medicine costs per PTT. With lower
levels of LDL-C simvastatin was the most cost-effective to use.
Atorvastatin was less effective and more costly than rosuvasta-
tin with all baseline LDL-levels and was therefore dominated.
CONCLUSION: The cost-effectiveness of statins depends on
patient’s cardiovascular risk proﬁle and baseline cholesterol
level. In Finland rosuvastatin is cost-effective in reaching Euro-
pean LDL-C target of 2.5 mmol/l when patient’s LDL-C level
exceeds 4.2 mmol/l.
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OBJECTIVES: Hypertension is an independent risk factor for
cardiovascular disease, which results in an enormous burden to
society, both in terms of health and costing. Therefore, health
gains and related cost-savings could be achieved by optimizing
antihypertensive treatment. The aim of this study was to esti-
mate the cost-effectiveness of treating patients with hyperten-
sion in The Netherlands with angiotensin II receptor blockers
(ARBs). METHODS: Our analysis comprised: 1) estimation of
the cost-effectiveness based on a published, prospective, ran-
domized, double-blind clinical trial comparing blood pressure
lowering of olmesartan, losartan, valsartan and irbesartan;
blood pressures at 8 weeks were inserted in the Framingham
risk functions to estimate cardiovascular complications,
using an international health economic model, and 2) a cost-
minimization analysis (assuming comparable effectiveness)
using daily practice prescription data from IADB.nl (50 phar-
macies), a database covering a population of 500,000.
RESULTS: After 8 weeks, the trial-based analysis showed that
with olmesartan versus losartan, valsartan, and irbesartan a
statistically signiﬁcant larger decrease in blood pressure was
achieved (11.5 versus 8.2, 7.9, and 9.9 mmHg [p < 0.05],
respectively). Furthermore, olmesartan resulted in most compli-
cations averted. Cost-effectiveness for olmesartan, losartan, val-
sartan, and irbesartan was estimated at €39,100, €77,100,
€70,700, and €50,900 per cardiovascular complication averted,
respectively. Pharmacy data showed that trial-dosing at 1
‘Deﬁned Daily Dose’ (DDD) was not found in practice. On
average, losartan, valsartan and irbesartan were consequently
dosed above 1 DDD varying from 1.19 to 1.38 ‘Prescribed
Daily Dose’ (PDD), whereas olmesartan was dosed at 0.88
PDD and thus presenting (relatively) lower costs. CONCLU-
SION: Olmesartan was estimated to be the most cost-effective
option of the four ARBs. However, due to differences found in
within-trial versus daily practice dosing and absence of effec-
tiveness data from daily practice, conﬁrmation is needed from
further prospective studies comparing ARBs based on compa-
rable blood pressure control including hard endpoints.
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OBJECTIVES: Despite considerable improvements in the treat-
ment of ST-elevated myocardial infarction (STEMI), patients
remain at long-term risk of additional cardiovascular (CV) events
(such as MI, stroke or vascular death). Over a four week treat-
ment period, the CLARITY-TIMI 28 and COMMIT/CCS-2 trials
demonstrated that clopidogrel (with and without loading dose,
respectively), administered in addition to standard therapy,
reduces the rate of mortality, infarct-related artery patency or MI
(RR 0.64 95% CI 0.53–0.76) and death, reinfarction or stroke
(0.91; 0.86–0.97), respectively. The aim of this study was to
assess the incremental cost per QALY (ICQ) of clopidogrel for
either one month or one year, in addition to standard care in
STEMI patients, from a UK perspective. METHODS: A cohort
Markov model described the experience of new CV events (MI
and stroke) prior to death in patients diagnosed with STEMI. UK
relevant STEMI baseline event rates were synthesised using data
from the literature and observational databases. Event rates in
clopidogrel patients were estimated by applying the aggregate
RRs from the respective trials to the baseline event rates. Health
state costs were derived from relevant UK-based costing studies
and updated to 2006 values, utility values were derived from the
broader literature. Costs and QALYs were discounted at 3.5%, a
full range of deterministic and probabilistic sensitivity analyses
were undertaken. RESULTS: For the 1-month and 1-year treat-
ment options both trials have mean ICQs below 2,500 and
4,000, respectively. In univariate sensitivity analyses the ICQ
never rose above 10,000. The probabilistic sensitivity analysis
showed that in all four analyses, clopidogrel was over 95% likely
to be cost-effective at a QALY value of 20,000. CONCLU-
SION: The estimated ICQs for both treatment options and for
both trials suggest that clopidogrel plus standard therapy is a
cost-effective alternative to standard therapy alone based on
current willingness to pay thresholds.
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OBJECTIVES: Ambulatory hypertension treatment is effective in
reducing mortality and morbidity due to cardiovascular diseases.
There are published evidences of under treatment of hyperten-
sion instead of the existing choice among lots of antihypertensive
medicines. This study aims to explore the antihypertensive medi-
cines prescribing and cost of hypertension therapy in Bulgaria
from the outpatient practice perspective. METHODS: A repre-
sentative sample of 2105 reimbursable prescriptions was col-
lected on a retrospective basis within one year. The prescriptions
were systematized according to the complexity of the therapy
(mono-, di-, three), INN, frequency of the prescribed brand
names of medicines, reimbursement drug prices, as well as,
patient co-payment. To calculate the cost of the outpatient
therapy was build the decision tree model. It matches the differ-
ences in the frequency of particular brand names prescribing and
their prices, as well as the cost dependence on complexity of the
therapy. RESULTS: The ACE inhibitors are the ﬁrst treatment
choice (41%, CI 95%) in the prescriptions, following by beta
blockers 19.43% and calcium channel blockers with 15.2%
share. The prescriptions with one medicine are 61%, di therapy
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is observed in 31%, and 8% are with three medicines. Using the
“decision tree” model the monthly cost of mono therapy is 9.71
BGL, for di therapy is 17.77 BGL and three therapy is 25.24 BGL
(exchange rate 1.95 BGL = 1 EURO). The total yearly cost of
outpatient therapy accounts for approximately 242 million BGL
with 65% patients’ co-payment. Sensitivity analysis shows that
the cost of the therapy is inﬂuenced more on changes in the price
of medicines than on therapy complexity. CONCLUSION: The
hypertension is an expensive disease with heavy burden of
co-payment for the Bulgarian patients.
PCV41
COSTS AND LENGTH OF STAY IN PATIENTS HOSPITALIZED
FOR ACUTE HEART FAILURE
Ondrackova B1, Miklik R2, Parenica J2, Spinar J2, Sticha M1
1Masaryk University, Brno, Czech Republic, 2Faculty Hospital Brno,
Brno, Czech Republic
OBJECTIVES: Using retrospective cost analysis was to estimate
direct in-patient costs and length-of-stay (LOS) in hospital for
acute heart failure (AHF) with one-year follow-up. METHODS:
Patients were hospitalized with acute decompensation (ADHF)
or new-onset of AHF in the Faculty Hospital Brno from January
till December 2005. Burden incurred is divided to standard car-
diology unit (SCU) and intensive care unit (ICU). In-patient care
costs include ﬂat rate of admission, stay and medicinal proce-
dures. The pharmaceuticals are included in daily in-patient rate;
angiography, revascularisations and antiarrhytmics are calcu-
lated separately. The subsequent hospitalizations were followed
for one year. RESULTS: In total, 734 patients (57% male, mean
age 71.7 years) with AHF were analysed. New-onset of AHF
(58.6%) was more common than ADHF; according to the clini-
cal classiﬁcation AHF with mild signs and symptoms prevailed
(46%). The overall direct hospital cost of all patients within
ﬁrst hospitalization was €2.4 million, LOS 8.3 days and mean
in-patient cost was €3295 (including all interventions). Mean
LOS in the SCU was 8.3 days with one-day cost of €55;
mean LOS in the ICU was 3.4 days with one-day cost of €618.
Cardiogenic shock was associated with highest hospitalization
costs (€4156). Total cost of cardiac cathetrisations and revascu-
larisations (50% patients) was €952,247; cost of antiarrhytmic
interventions (PM and ICD; 6.9% patients) was €529216. Mor-
tality during ﬁrst hospitalization was 14.6%. Most patients were
hospitalized due to AHF within 1–3 months after ﬁrst admission
without relation between hospitalization rates. CONCLUSION:
AHF hospitalization is a signiﬁcant source of health care expen-
ditures and has become more frequent as the population ages and
medical care improves survival after acute coronary syndromes.
AHF is associated with poor prognosis and high costs during
hospital admission; the predominant contributors of high costs
are revascularisation procedures (40%), stay in the ICU (31%)
and antiarrhytmic interventions (22%).
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OBJECTIVES: The purpose of the study was to evaluate the
economic burden directly borne by the patient affected with
Atrial Fibrillation, and the satisfaction associated with monitor-
ing of Oral Anticoagulation Therapy (OAT) in different settings
of care, in an Italian Region (Umbria). METHODS: A prospec-
tive, observational and multi-centre (5 centres: 3 anticoagulation
clinics—ACs—and 2 usual settings of care—USCs) study was
designed. Data were collected through case report forms created
ad hoc. Study perspective was the patient’s, thus the costs sus-
tained by the Italian NHS were excluded, and only direct non-
health care costs (out-of-pocket expenses covered either by the
patient or by caregivers for non-health care related services) and
patient’s and caregiver’s productivity losses were taken into
account. Satisfaction with anticoagulation management was
measured by the speciﬁc Duke Anticoagulation Satisfaction scale
(DASS), together with the generic quality of life SF-36 form, both
administered at day one and at the end of the observation period.
RESULTS: A total of 101 patients in ACs and 51 in USCs were
consecutively enrolled. The number of monitoring performed on
a yearly basis resulted 3.5 tests less (-17%) for ACs compared to
USCs (p-value 0.000), while the total time spent of each control
was 7.1 hours less (-47%) for ACs (p-value 0.000). Direct non-
health care costs and production losses per patients on a yearly
basis amounted to an average of Euro 274.5 without signiﬁcant
differences amongst ACs and USCs. DASS in ACs resulted on
average 0.5 points lower than USCs (p-value 0.001): patients in
ACs felt less limitations on physical activities (-0.8 points,
p-value 0.001), hassles (-1.0 points, p-value 0.000) and burdens
(-0.6 points, p-value 0.001). The SF-36 did not detect any sig-
niﬁcant difference in the general health status. CONCLUSION:
ACs appears to be the preferred setting of care for OAT moni-
toring when considering patient’s perspective.
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OBJECTIVES: Global cardiometabolic risk represents the
overall risk of developing type 2 diabetes (T2DM) and/or car-
diovascular disease (including MI and stroke), which is due to a
cluster of modiﬁable risk factors/markers. The objective of our
study is to determine the direct medical costs imposed on the
Insurer in Hungary relation with the treatment of the most
important cardiovascular diseases and T2DM. METHODS:
Individual-level treatment data of 16,880 patients suffering of
Acute myocardial infarction (AMI), angina, stroke, and transient
ischemic attack (TIA) and having primary care at a inpatient
institute were processed by using ﬁnancing database containing
reimbursement data of 2-year outpatient and inpatient cares The
mean costs of cardiovascular disease were divided into sub-costs
of acute treatment and of 6-month follow-up treatment. Cost of
T2DM was calculated using a doctor’s questionnaire assessing
the probability (frequency) of interventions, and treatments
speciﬁed in the current guideline. 2005 price level were used.
RESULTS: The mean acute treatment costs of AMI was €932
(fatal) and €2017 (non-fatal); of angina was €1489; of stroke was
€935 (fatal) and €1056 (non-fatal); of TIA was €781 to the
Insurer. The 6-month follow-up cost in case of 2TDM was €350,
AMI was €2006, angina was €1679, stroke was €3110 and TIA
was €1749. CONCLUSION: According to our calculations, the
main complications of cardiometabolic risk represent signiﬁcant
expenses to the Insurer. The results give opportunity to evaluate
the cost-effectiveness of health technologies used in the manage-
ment of cardiometabolic risks factors.
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